Bharat Biotech's partner seeks Covaxin nod in US for children between 2 and 18 years

The US-based firm has applied for the authorisation based on the basis of the results of phase 2 and 3 clinical trials conducted on 526 children aged between 2 and 18 years of age in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3wo2L3a
via IFTTT